IPP Bureau
ICON selected by BARDA to conduct anthrax vaccine clinical trial
By IPP Bureau - October 09, 2022
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
Glenmark launches Lobeglitazone in India for Uncontrolled Type 2 Diabetes in adults
By IPP Bureau - October 07, 2022
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
Presss note on WHO Medical product alert regarding Maiden Pharmaceuticals
By IPP Bureau - October 07, 2022
DSCO has requested WHO to share at the earliest with CDSCO the report on establishment of causal relation to death with the medical products in question etc.
Zydus receives final approval from USFDA and 180 days shared exclusivity for Brivaracetam Tablets
By IPP Bureau - October 07, 2022
Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
L&T Construction bags order to construct manufacturing facility in Haryana
By IPP Bureau - October 07, 2022
This win is on the back of a prestigious order from Reliance Life Sciences
Lupin appoints Dr. Shahin Fesharaki as Global Chief Scientific Officer
By IPP Bureau - October 07, 2022
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Atul Healthcare to acquire stake in VIMS
By IPP Bureau - October 05, 2022
The agreement provides for acquisition of 13,50,000 equity shares of Rs. 100 each constituting 50% of the total equity share capital
Granules India inaugurated water tank at Bonthapally village
By IPP Bureau - October 05, 2022
The two overhead tanks commissioned at a cost of Rs 57 lakh will be maintained by the village panchayats.
NATCO launches Chlorantraniliprole combination agro products in India
By IPP Bureau - October 05, 2022
Both products are broad-spectrum, foliar insecticides used across wide range of crops
Lupin receives approval from USFDA for Darunavir Tablets
By IPP Bureau - October 05, 2022
The product will be manufactured at Lupin's facility in Nagpur, India.
Casper Pharma receives EIR from USFDA for its PAI
By IPP Bureau - October 05, 2022
The inspection concluded with no observation (FDA-483) issued.
Medcare acquires 60% stake in Skin III
By IPP Bureau - October 05, 2022
This acquisition will accelerate Medcare's plans to emerge as an international hub for health, beauty, and wellness adding to its existing network of 4 hospitals and over 20 medical centres in the UAE.
Zydus receives USFDA tentative approval for Amantadine Extended-Release capsules
By IPP Bureau - October 05, 2022
Amantadine Extended-Release capsules had annual sales of US $2.7 million in the United States according to IQVIA data
Wockhardt Hospitals, Mira Road starts a Comprehensive Clinic for Cancer Patients
By IPP Bureau - October 05, 2022
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
Zydus receives approval from USFDA for Mirabegron Extended-Release Tablets
By IPP Bureau - October 04, 2022
Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency
